TrialDiabetes, obesity & metabolism2020

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.

Subodh Verma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.